SIGA Technologies Valuation
Is SIGA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
PM vs Fair Ratio
Share Price vs Fair Value
What is the Fair Price of SIGA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SIGA ($5.32) is trading below our estimate of fair value ($9.39)
Significantly Below Fair Value: SIGA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SIGA?
Other financial metrics that can be useful for relative valuation.
|What is SIGA's n/a Ratio?
Price to Sales Ratio vs Peers
How does SIGA's PS Ratio compare to its peers?
PROC Procaps Group
TBPH Theravance Biopharma
PAHC Phibro Animal Health
SIGA SIGA Technologies
Price-To-Sales vs Peers: SIGA is expensive based on its Price-To-Sales Ratio (10.9x) compared to the peer average (6.6x).
Price to Earnings Ratio vs Industry
How does SIGA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: SIGA is expensive based on its Price-To-Sales Ratio (10.9x) compared to the US Pharmaceuticals industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is SIGA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio
|Fair PS Ratio
PM vs Fair Ratio: SIGA is good value based on its Price-To-Sales Ratio (10.9x) compared to the estimated Fair Price-To-Sales Ratio (12.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.